Viatris Inc: directors' dealings · United States · SEC (Form 4)

About Viatris Inc

Viatris Inc. is a global pharmaceutical company listed in the United States on the Nasdaq market under ticker VTRS, and headquartered in Pittsburgh, Pennsylvania, United States. The company was formed in 2020 through the combination of Mylan and the Upjohn business carved out of Pfizer, with the stated goal of creating a more diversified healthcare platform spanning generic medicines, established branded products and selected specialty assets. For international investors, Viatris represents a large-cap healthcare name with a defensive profile, broad geographic reach and meaningful exposure to recurring pharmaceutical demand. Viatris’ business model is built on a wide commercial footprint across Developed Markets, Greater China, Japan/Australia/New Zealand, and Emerging Markets. That geographic diversification helps the company participate in healthcare demand across multiple regions while balancing regulatory, pricing and reimbursement risks. Its portfolio is extensive and includes hundreds of approved molecules across multiple therapeutic areas, such as chronic disease treatments, hospital products, ophthalmology, cardiovascular care, dermatology, gastroenterology and anti-infectives. The company also combines its generics platform with a set of established branded medicines and certain specialty assets, which supports a more balanced revenue mix than a pure-play generic manufacturer. From a competitive standpoint, Viatris operates in a highly regulated and intensely competitive industry where pricing pressure, supply reliability, manufacturing quality and market access are critical. Its scale, breadth of portfolio and global infrastructure are key competitive advantages, especially in categories where purchasing power and operating efficiency matter. The company has also been working to strengthen its growth profile through new product launches and a development pipeline that includes complex generics, branded opportunities and targeted specialty programs. Recent developments have been important for the equity story. In February 2026, Viatris reported full-year 2025 total revenues of $14.3 billion and said it had completed its enterprise-wide strategic review, targeting $650 million in total cost savings with some reinvestment to support future growth. During 2025, the company also announced several regulatory milestones, including U.S. approval of a generic version of Sandostatin LAR Depot, progress on a low-dose estrogen weekly patch, and additional pipeline updates in Japan. In parallel, Viatris completed the sale of its stake in Biocon Biologics in 2026, underscoring active capital allocation and portfolio optimization. Overall, Viatris remains a major global pharmaceutical platform with diversified international exposure, a broad medicines portfolio and a disciplined financial profile on the Nasdaq market in the United States.